Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
This study evaluated the effectiveness and safety of sintilimab combined with cCRT in patients with locally advanced ESCC.
Locally Advanced Esophageal Squamous Cell Carcinoma
DRUG: Sintilimab|DRUG: Chemotherapy|RADIATION: Radiation Therapy
PFS, progression-free survival (PFS) refers to the time from enrollment to the first recording of disease progression as determined by RECISTv1.1, or to death due to any cause (whichever occurs first). PFS will be analyzed in the ITT analysis set., up to 3 years
ORR, Objective response rate, according to RECISTv1.1, the proportion of patients with CR or PR was determined. If the patient has not undergone a post-baseline assessment, it is considered unremission., up to 3 years|Overall survival (OS, OS refers to the time from enrollment to the first recorded death due to any cause (whichever occurs first)., up to 5 years|HRQoL, HRQoL uses EORTCQLQ-C30 to assess the overall health of patients. The post-baseline score of the treatment group was studied, and the score changes from the baseline were summarized descriptively., up to 3 years|HRQoL, HRQoL uses EORTCQLQ-OES18 to assess the overall health of patients. The post-baseline score of the treatment group was studied, and the score changes from the baseline were summarized descriptively., up to 3 years
This study evaluated the effectiveness and safety of sintilimab combined with cCRT in patients with locally advanced ESCC. The primary endpoint is PFS. Secondary points contains：ORR、OS、Qol.